Analytical Data
-
Gene name
MSLN
- Application
-
Alternative Names
SMR; MPF; CAK1; Pre-pro-megakaryocyte-potentiating factor; Megakaryocyte-potentiating factor
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13421
-
Expression Region
Glu296~Ser606
-
Molecular Weight
42&46kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MSLN, or Mesothelin, is a glycoprotein that is overexpressed in several malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer, making it a significant target for cancer immunotherapy. The interest in MSLN has been fueled by its role as a tumor marker and its potential use in targeted therapies, particularly those involving monoclonal antibodies and adoptive T cell therapies. Research on recombinant MSLN proteins has advanced our understanding of its biological functions and its interactions with immune cells. Studies have shown that MSLN can facilitate tumor progression and may modulate the immune response, thereby providing a double-edged sword in cancer biology. The ability to produce recombinant MSLN has enabled the development of novel diagnostic tools and therapeutic agents aimed at harnessing the immune system to combat cancer. By elucidating the structure and function of MSLN, researchers are exploring its application in vaccines and adoptive cell transfer strategies. The therapeutic potential of MSLN-targeted approaches is underscored by ongoing clinical trials evaluating MSLN-specific agents, highlighting the importance of this protein in the quest for more effective cancer treatments. As research continues, MSLN remains a focal point for understanding tumor biology and developing innovative therapeutic interventions.
